# Transgenic and Genome Editing Facility (TGEF-SR)

> **NIH NIH P30** · PURDUE UNIVERSITY · 2020 · $191,772

## Abstract

Transgenic and Genome Editing Facility Shared Resource (TGEF-SR)
 Project Summary
 The ability to introduce foreign genes into the germ line, to selectively ablate endogenous genes, or to
genetically edit specific genes in the mouse and rat genome, has proven to be one of the most powerful
experimental tools available for understanding specific genetic requirements for tumor promoting regulatory
pathways. In the area of oncology, genetically engineered mouse models have revealed the molecular pathways
by which proto-oncogenes predispose cells to develop malignant tumors or how tumor suppressor genes
maintain normal growth control. Transgenic strategies have also revolutionized the way we approach the
complex problems associated with carcinogenesis, including the development of novel therapeutic intervention
strategies. To support cancer research and utilization of this powerful technology, the Purdue University Center
for Cancer Research (PCCR) Transgenic and Genome Editing Facility Shared Resource (TGEF-SR) was
established in 1998. The PCCR's TGEF-SR is a state-of-the-art facility that offers a large number of services to
the Center membership, including the creation of transgenic, knock-out, and gene-edited mouse and rat models
that can assist in dissecting transcriptional, signaling, and environmental influences on tumor initiation,
progression and metastasis. Additionally, these models have been instrumental in dissecting the importance of
immune cells and stromal infiltrates to tumor progression, and have helped to identify novel cancer stem cell
lineages that are often resistant to conventional chemotherapeutics. The TGEF-SR provides a wide range of
services to the PCCR community that can be divided into 2 main categories, genome editing and assisted
reproduction. The Resource offers several options for gene editing, including: (i) traditional transgenic
technology to produce animals with exogenous gene sequences randomly inserted into the genome; (ii)
CRISPR-mediated knock-outs to delete small or large, targeted pieces of DNA, resulting in gene disruption or
inactivation; (iii) CRISPR-mediated, targeted, homology-directed knock-ins of DNA sequences to produce subtle
changes in gene sequence; (iv) insertion of large cassettes or entire gene replacements; and (v) traditional
knock-outs produced by injection of gene-targeted ES cells into blastocysts. The last few years has seen a major
shift towards CRISPR-mediated projects, with 31 CRISPR/cas9 projects, in both rats and mice, completed in a
3-year period. In support of genetically engineered rodent colonies, the TGEF-SR also offers services to assist
with the maintenance of mouse colonies and to overcome difficulties associated with breeding challenging lines,
including re-derivation by embryo transfer to import new lines from outside facilities, embryo and sperm
cryopreservation to preserve the valuable gene-edited lines generated, and in vitro fertilization to overcome
breeding problems o...

## Key facts

- **NIH application ID:** 10024909
- **Project number:** 2P30CA023168-40
- **Recipient organization:** PURDUE UNIVERSITY
- **Principal Investigator:** STEPHEN F KONIECZNY
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $191,772
- **Award type:** 2
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10024909

## Citation

> US National Institutes of Health, RePORTER application 10024909, Transgenic and Genome Editing Facility (TGEF-SR) (2P30CA023168-40). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10024909. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*